Serologic Response to the Epstein-Barr Virus Peptidome and the Risk for Multiple Sclerosis

Area of Science:

• Neuroimmunology
• Virology
• Epidemiology

Background:

• The link between Epstein-Barr virus (EBV) infection and multiple sclerosis (MS) is established, but the specific mechanisms and serologic markers remain unclear.
• Only a small fraction of EBV-infected individuals develop MS, indicating a need to identify specific immune responses that predict disease development.

Purpose of the Study:

• To investigate the antibody response to the entire EBV peptidome in individuals before the onset of MS.
• To determine if a distinct immune response to EBV is associated with MS development.
• To evaluate if specific EBV epitopes are selectively targeted in individuals who develop MS.

Main Methods:

• A prospective, nested case-control study using serum samples from US military personnel.
• Antibody responses to 2263 EBV peptides were measured using VirScan technology.
• Conditional logistic regression was used to estimate rate ratios for MS, adjusting for total anti-EBV nuclear antigen 1 (EBNA-1) antibodies.

Main Results:

• Individuals with MS showed a stronger antibody response to the EBV peptidome compared to controls.
• Antibody responses to 66 EBV peptides, primarily mapping to EBNA antigens, were significantly higher in pre-MS sera.
• After adjusting for total anti-EBNA-1 antibodies, the association with most EBV peptides was attenuated, but the link between anti-EBNA-1 antibodies and MS risk persisted.

Conclusions:

• Antibody response to EBNA-1 appears to be the strongest identified serologic risk factor for MS.
• No single EBV peptide was uniquely targeted in MS cases.
• Further research is needed to understand the heterogeneity of anti-EBV humoral immunity in MS.